Autopsy report · NCT05288023
Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)
Cause of deathOther
“AVENIR I demonstrated efficacy of azithromycin MDA targeted to children 1-59 over 1-11 months in July 2023, thus this trial was stopped before outcomes were collected so Niger could expand the program nationally to include children 1-59 months.”
Life of this trial
- Registered 9 months before it started.
- Ran for about 1 year 1 month before it stopped.
- 169,707 participants enrolled.
- Results were posted on the registry 1 year 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Conditions
- Resistance Bacterial; Morality; Child Health; Implementation
- Interventions
- Azithromycin for Oral Suspension
- Participants
- 169,707
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.